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ABSTRACT
Background: The importance of smoking in bronchial asthma has been thoroughly investigated. Although a
high smoking rate has been recognized in Japan, there have been few studies of the relationship between ac-
tive smoking and bronchial asthma, and little analysis of the gender difference in this relationship. The aims of
this study were to examine the contribution of active smoking to asthma and to clarify any gender difference.
Methods: For 8 weeks from September through October 2000, a smoking questionnaire survey was per-
formed on adult patients with bronchial asthma, and their attending physicians, in Niigata Prefecture, Japan.
The questionnaire surveyed asthma control, asthma-related emergencies and satisfaction in daily life. The at-
tending physicians were questioned about patient profiles and medications. Patients were classified into three
groups : non-smokers (NS), ex-smokers (ES) and current smokers (CS). For examination of gender differ-
ences, the CS group was compared with the NS group, due to variable duration of smoking and of cessation of
smoking in the ES group.
Results: Complete data were received from 2947 cases. Of the male patients, 340 (23.0%) were in the CS
group, 325 (22.0%) were in the NS group and 812 were in the ES group. Of the female patients, 109 (7.4%)
were in the CS group, 1132 (77.4%) were in the NS group, and 229 (7.4%) were in the ES group. The male CS
group had more severe asthma-related symptoms in the morning and at night, more sputum and cough in the
morning, and more severe sleep disturbance than the male NS group. In the female patients, these differences
were not detected. A logistic and multiple regression analysis confirmed these significant differences between
male and female asthma patients.
Conclusions: The gender differences in the susceptibility of asthma to smoking suggests the need for
gender-specific strategies for smoking cessation, although further investigation is required.
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INTRODUCTION
Active cigarette smoking is common in adult asthma
patients, and their prevalence rates are likely to be
similar to the general population.1 The current smok-
ing rate among asthma patients ranges from 17% to
35% . 2-9 Because the pathogeneses of bronchial
asthma is thought to be inflammation of the bronchi
that leads to bronchial hypersensitivity and bronchial
airflow limitation , 10 the influence of smoking was
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Table 1 Contents of the questionnaire used for asthmatic patients in this study (originaly in Japanese.)
Age:　　　　years old　　　　Gender: male/female
Question 1
When were you first diagnosed as having bronchial asthma?　　Year:　　Month:　　Day:
Question 2
1) Choose one of the folowing to describe your smoking
(non-smoker, ex-smoker, curent smoker)
2) For ex-smokers, please answer the folowings:
How old were you when you started smoking? Your starting age:
How old were you when you stopped smoking? Your stopping age:
How many cigaretes did you smoke per day? Cigaretes/day (mean):
Was stopping smoking related to your asthma? Yes or No:
3) For curent smokers, please answer the folowing:
How old were you when you started smoking? Your starting age:
How many cigaretes did you smoke per day? Cigaretes/day (mean):
Question 3
1) Do you use a peak-flow meter?　　(Yes, No)
2) What was the average value of your peak-flow meter during the last 2 weeks?
morning:　　　　　night:
Question 4 Select one answer to each of the folowing questions:
1) How often did you have asthma atacks during the last 12 months?
　(frequent atacks, seasonal atacks, few atacks)
2) How often did you have asthma atacks during the last 2 weeks?
　(5―7/week, 3―4/week, 1―2/week, non)
3) How severe were your asthma atacks during the last 2 weeks?
　(impossible to move, impossible to lie down, possible to lie down, stridor, breathless on exertion)
4) Have you ever been hospitalized due to asthma?
　(Yes, No)
5) Have you ever been taken by ambulance or visited an emergency room due to an asthma atack?
　(Yes, No)
6) Have you ever been placed on a respirator due to an asthma atack?
　(Yes, No)
7) Have you ever been unconscious during an asthma atack?
　(Yes, No)
8) Have you ever had an atack induced by anti-inflammatory drugs including painkilers, antipyretics, or cold medicine?
　(Yes, No)
Question 5 How bad was your asthma during the last 2 weeks?
　(very good, fairly good, mediocre, slightly bad, bad)
Question 6 Describe your symptoms during the last 2 weeks:
1) in the morning
　(cough, sputum, chest tightness, stridor, dyspnea, no symptoms)
2) at night
　(cough, sputum, chest tightness, stridor, dyspnea, no symptoms)
3) sleep disturbance
(sometimes cannot fal asleep due to dyspnea, cannot to have a good sleep due to dyspnea, waking up in the night due 
to chest tightness, none)
Question 7
Are you satisfied in daily life?
　(very satisfied, fairly satisfied, mediocre, slightly unsatisfied, not satisfied)
brought to the attentions of these asthmatic
stages.11-13 The influence of smoking on the thera-
peutic response to corticosteroids has been reported.
14 However, it is important to study the clinical impli-
cations of active smoking, and few such studies have
been performed in Japan.
It is well known that disease profiles and factors as-
sociated with diseases can vary by sex. In respiratory
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Table 2 Adult bronchial asthma severity assessment 
commitee’ sstandards of the Japanese Society of Alergol-
ogy
Severity of symptoms
frequency
D (D1/D2)CBA
moderatemoderateseveresevere5―7/week
mildmoderatemoderatesevere3―4/week
mildmildmoderatesevere1―2/week
A: impossible to move due to dyspnea, B: impossible to lie 
down due to dyspnea, C: possible to lie down even with dysp-
nea, D1: stridor alone, D2: chest tightness alone
diseases , gender differences of the bronchi have
been reported . 15 Although cigarette smoking is
thought to cause more respiratory symptoms and
greater deterioration in lung function in women than
in men,16,17 this is controversial.18 In the management
of bronchial asthma, some have reported that women
are more affected by smoking than men.19,20 How-
ever, the gender difference with regard to the influ-
ence of active smoking on asthma patients in Japan is
unclear , because Japan differs in race and lifestyle
from the countries where such analyses were per-
formed.
A questionnaire survey was conducted by the Nii-
gata Asthma Treatment Study Group, taking these
factors into consideration. Subjects from this survey
were adult patients with bronchial asthma who visited
medical institutions in the Niigata Prefecture, starting
in 1998. The attending physicians of these patients
were included in the survey. Based on this survey, we
have reported the clinical characteristics of adult
bronchial asthma patients,21 the characteristics of eld-
erly bronchial asthma patients 22 and changes in
asthma management.23
At the beginning of this survey , there were no
questions about active cigarette smoking; these ques-
tions were added in 2000. In this paper, the analysis
was based on results obtained from surveys con-
ducted from 2000 onwards, to examine the relation-
ship between asthma and active smoking, and any
gender difference.
METHODS
The questionnaire used in this study was performed
in Niigata Prefecture, Japan, under the Ethical Princi-
ples for Medical Research Involving Human Subjects,
Declaration of Helsinki . The institutions involved
were 32 large hospitals (200 beds or more), 24 small
hospitals (< 200 beds) and 44 clinics (no beds). Eight
thousand questionnaires were prepared and 3293
were answered (collection rate : 41.2%). The contents
of the questionnaire are shown in Table 1 (originally
in Japanese). The questionnaire was carried out over
2 months from September to October 2000. Subjects
were recruited from adult patients (aged 16 years and
over) with bronchial asthma who regularly visited the
participating institutions for asthma management
(typically once or twice per month). They were re-
cruited by their physician during a regular visit dur-
ing the study period . The recruited patients were
asked to complete the questionnaire by themselves
(Table 1). Therefore, the understanding of technical
terms such as“attack”or“unconscious”(Table 1)
depended upon individual patients．
For an evaluation of asthma control, patients were
asked about their mean peak expiratory flow value
(PEFV) and the presence of asthma attacks during
the two weeks prior to the questionnaire . The pa-
tients were also asked about their asthma during the
year prior to the questionnaire by choosing 1 of 3 an-
swers:“few attacks，”“seasonal attacks”or“frequent
attacks．”The questionnaire asked about asthma-
related symptoms in the two weeks prior to the ques-
tionnaire, including cough and sputum in the morn-
ing and at night, and sleep disturbance. The question-
naire also inquired about asthma-related emergen-
cies , including ambulance use , emergency depart-
ment visits and hospitalization , and life-threatening
events including unconsciousness during asthma at-
tacks, and attacks requiring respirator management,
and asthma attacks induced by anti-inflammatory-
agent (aspirin induced asthma). The subjects were
asked to answer“yes”or“no”to the following five
questions: “Have you ever been hospitalized due
to asthma？”，“Have you ever been taken by ambu-
lance or visited an emergency room due to an at-
tack？”，“Have you ever been placed on a respirator
due to an asthma attack？”，“Have you ever been un-
conscious during an asthma attack？”， and“Have
you ever had an attack induced by anti-inflammatory
drugs including painkillers , antipyretics , or cold
medicine？”To evaluate problems with asthma man-
agement and treatment related to normal activity lev-
els, the questionnaire asked patients about satisfac-
tion in daily life. The subjects answered by choosing
1 of 5 answers:“ very satisfied，”“ fairly satisfied，”
“mediocre，”“slightly unsatisfied，”and“not satis-
fied．”
At the time that the patient completed their ques-
tionnaire, their physician was asked to supply details
of current treatment, the type of asthma (atopic or
non-atopic, according to elevation of serum total IgE
or significant detection of specific IgE for allergens),
and the severity of asthma, using the adult bronchial
asthma severity assessment committee’s standards of
the Japanese Society of Allergology. As shown in Ta-
ble 2, severity was classified according to a combina-
tion of frequency and degree of attacks during the
worst 4 weeks prior to the questionnaire. However, in
cases of administration of corticosteroids , the total
dosage of corticosteroids , including inhaled corti-
costeroids, can independently define the severity. A
case was classified as“severe”with a dose of more
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Table 3-a Background and medication in male patients
curent smokers (n = 340)non-smokers (n = 325)
347 +/- 192Brinkman’ sindex (mean +/-SD)
50.5 +/- 16.651.6 +/- 19.0age (mean +/-SD)
16.6 +/- 21.1＊15.0 +/- 15.9duration (year: mean +/-SD)
70.3/22.1＊64.3/29.5type: % (atopic/nonatopic)
44.1/43.5/5.042.8/46.2/8.3severity: % (mild/moderate/severe)
 32.9 40.0rate of PEF use (%)
 59.7＊＊ 70.8rate of ICS use (%)
621 +/- 336561 +/- 173ICS dose (μg/day: calcuiated as BDP)
 10.0 10.8rate of OCS use (%)
7.0 +/- 3.96.3 +/- 2.8OCS dose (mg/day: calculated as PSL)
 33.2 36.9rate of LTRA use (%)
 74.1＊ 80.6rate of OSRT use (%)
 34.4 35.1use of SABA on demand
 2.1 2.2 regular
 32.1 36.0experience of ambulance or ED (%)
 37.1 41.2experience of hospitalization (%)
 4.7 6.5experience of UC (%)
 5.3 4.6experience of RM (%)
 6.2 6.8experience of AIA (%)
ICS: inhaled corticosteroid, BDP: beclomethasone dipropionate, OCS: oral corticosteroid, PSL: prednisolone, LTRA: leukotriene receptor 
antagonist, OSRT: oral susrained-release theopyhline, ED: emergency department, UC: unconsciousness due to asthma atacks, RM: res-
pirator management, AIA: aspirin induced asthma atack ＊: P < 0.05, ＊＊:P < 0.01 vs non-smokers
Table  3-b Background and drug medication in female patients
curent smokers (n = 109)non-smokers (n = 1132)
357 +/- 374Brinkman’ sindex (mean +/- SD)
44.3 +/- 16.5＊＊＊57.4 +/- 15.3age (mean +/- SD)
18.5 +/- 20.716.6 +/- 18.2duration (year: mean +/- SD)
70.6/22.963.3/31.1type: % (atopic/nonatopic)
35.8/55.0/3.7＊41.8/43.7/9.8severity: % (mild/moderate/severe)
 35.8 40.5rate of PEF use (%)
 73.4＊＊ 70.8rate of ICS use (%)
589 +/- 259606 +/- 353ICS dose (μg/day: calcuiated as BDP)
 6.4＊ 14.5rate of OCS use (%)
6.1 +/- 2.75.6 +/- 2.7OCS dose (mg/day: calculated as PSL)
 32.1 33.0rate of LTRA use (%)
 70.6 74.5rate of OSRT use (%)
 31.2 29.0use of SABA on demand
 2.8 2.8 regular
 59.7＊＊＊ 35.7experience of ambulance or ED (%)
 48.6 46.1experience of hospitalization (%)
 2.8 7.1experience of UC (%)
 7.3 6.4experience of RM (%)
 11.0 11.4experience of AIA (%)
ICS: inhaled corticosteroid, BDP: belcomethasone dipropionate, OCS: oral corticosteroid, PSL: prednisolone, LTRA: leukotriene receptor 
antagonist, OSRT: oral susrained-release theophyline ＊:P < 0.05, ＊＊:P < 0.01, ＊＊＊:P < 0.001 vs non-smokers
than 10 mgday, and“moderate” with a dose of 5―10
mgday, calculated for prednisolone.
Patients were classified into three groups : non-
smokers (NS), ex-smokers (ES) and current smokers
(CS). The CS group was mainly compared with the
NS group, because of varied duration of smoking and
of cessation of smoking in the ES group．
The results were expressed as arithmetic means
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Table 4-a Presence of asthma atacks, peak flow values, asthma-related symptoms and sleep disturbance in male patients 
during the two weeks prior to questionnaire
curent smokers (n = 340）non-smokers (n = 325)
 40.0 32.6PA (%)
443 +/- 139 (n = 98)＊＊＊473 +/- 125 (n = 122)PEFV (morning, mean +/- SD)
453 +/- 147 (n = 94)＊＊＊484 +/- 128 (n = 117)PEFV (night, mean +/- SD)
 64.4＊＊＊ 45.5ARS in the morning (%)
 24.7＊＊ 19.1sputa in the morning (%)
 33.5＊＊＊ 17.5cough in the morning (%)
 43.5＊ 34.8ARS at night (%)
 14.4 11.7sputa at night (%)
 12.9 10.8cough at night (%)
 29.1＊＊ 19.7sleep disturbance (%)
PA: presence of asthma atacks, PEFV: peak flow value, ARS: asthma related symptoms ＊: P < 0.05, ＊＊: P < 0.01, ＊＊＊: P < 0.001 
vs non-smokers
Table 4-b Presence of asthma atacks, peak flow value, asthma-related symptoms and sleep disturbance in female patients 
during the two weeks prior to questionnaire
curent smokers (n = 109)non-smokers (n = 1132)
 36.4 33.0PA (%)
374 +/- 83 (n = 35)＊＊328 +/- 92 (n = 396)PEFV (morning, mean +/- SD)
387 +/- 81 (n = 34)＊＊339 +/- 91 (n = 392)PEFV (night, mean +/- SD)
 57.8 52.8ARS in the morning (%)
 22.9 21.9sputa in the morning (%)
 26.6 21.7cough in the morning (%)
 41.3 39.8ARS at night (%)
 14.7 11.1sputa at night (%)
 7.3 9.1cough at night (%)
 29.4 30.5sleep disturbance (%)
PA: presence of asthma atacks, PEFV: peak flow value, ARS: asthma related symptoms ＊＊: P < 0.01 vs non-smokers
Table 5-a　Asthma atacks in males during the year prior 
to the questionnaire
seasonal/few/frequent/not answered (%)
116/134/43/32 (35.7/41.2/13.2/9.8)
nonsmokers
(n = 325)
140/99/49/52 (41.2/29.1/14.4/15.3)＊
curent smokers
(n = 340)
＊: P < 0.05 vs curent smokers
Table 5-b　Asthma atacks in females during the year prior 
to the questionnaire
seasonal/few/frequent/not answered (%)
399/443/150/140 (31.6/41.3/14.0/13.1)
nonsmokers
(n = 1132)
49/38/13/9 (45.0/34.9/11.9/8.3)
curent smokers
(n = 109)
(±SD)for continuous variables. A Mann-Whitney U
test was used to test the equality of distributions of
continuous variables . Differences between dichoto-
mous variables were analyzed using the chi-square
test. These tests were performed with Bonferroni’s
correction for the significance level. A logistic or mul-
tiple regression analysis was used to identify the fac-
tors influencing each dependent variable. All statisti-
cal analyses were performed using statistical software
StatView 5.0 PowerPC version (SAS Institute Inc . ,
Cary, NC, USA), BMDP 3S (BMDP, Los Angeles,
CA) and Statxact (Cytel Software Co. , Cambridge,
MA, USA). For all statistical analyses, a P value of
less than 0.05 was considered to be statistically sig-
nificant.
RESULTS
PATIENT BACKGROUND AND DRUG MEDICA-
TION
Patient background and medication usage in the CS
and NS groups are summarized in Table 3. In this
study, 3293 patients responded. Of the male patients,
325 (22.0%) were classified as NS, 812 (57.0%) were
classified as ES, and 340 (23.0%) were classified as
CS. Of the female patients, 1132 (77.0%) were classi-
fied as NS, 229 (15.6%) were classified as ES and 109
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Table 6-a Satisfaction in daily life in male
very satisfied, fairly satisfied, mediocre, slightly unsatisfied, not satisfied (%)
45/193/48/27/5 (14.2/60.7/15.1/8.4/1.6)non-smokers (n = 325)
36/176/77/39/5 (11.3/55.4/24.2/12.3/1.6)＊curent smokers (n = 340)
＊; P < 0.05 vs non-smokers
Table 6-b Satisfaction in daily life in female
very satisfied, fairly satisfied, mediocre, slightly unsatisfied, not satisfied (%)
115/660/161/112/15 (14.1/59.8/14.6/10.1/1.4)non-smokers (n = 1132)
16/51/26/12/4 (14.7/46.8/23.9/11.0/3.7)＊curent smokers (n = 109)
＊;P < 0.05 vs non-smokers
Table 7-a Variables
categorytype of variablesvariables
NS (0), ES (1), or CS (2)discretesmoking
continuousage
continuousonset age of disease
continuousduration of disease
No (0) or Yes (1)discretepeak flow monitoring
mild (0), moderate (1), or severe (2)discreteseverity of disease
atopic asthma (0), non-atopic asthma (1)discretetype of asthma
No (0) or Yes(1)discreteuse of oral sustaind-relaese theophyline
No (0), as-needed (1), regular use (2)discreteuse of short-acting beta 2 agonist
No (0) or Yes (1)discreteuse of oral corticosteroid
continuousdose of inhaled steroid calculated as BDP
No (0) or Yes (1)discreteuse of antihistamines
No (0) or Yes (1)discreteuse of leukotriene receptor antagonists
continuousBrinkman’ sindex
Continuous variables were standardized to a mean of 0 and standard deviation of 1. CS: curent smoking, ES: ex-smoking, NS: nonsmok-
ing
Table 7-b Dependent variables
categoryvariables
No (0) or Yes (1)ARS in the morning
No (0) or Yes (1)sputa in the morning
No (0) or Yes (1)cough in the morning
No (0) or Yes (1)ARS at night
No (0) or Yes (1)sputa at night
No (0) or Yes (1)cough at night
No (0) or Yes (1)sleep disturbance
No (0) or Yes (1)experience of ambulance or emergency department
No (0) or Yes (1)experience of unconsciousness due to asthma atacks
No (0) or Yes (1)experience of respirator management
No (0), with seasonal episodes (1), or always (2)frequency of asthma atacks during a year
No (0), 1 to 2 times (1), 3 to 4 times (2), or more than 5 times (3)number of asthma atacks in this two weeks
No symptoms (0), wheeze only (1), symptoms were minimaly trou-
blesome (2), symptoms were severe but able to lie down (3), symp-
toms were so severe as toprevent a lie down (4), or symptoms were 
so severe as to prevent any movement (5)
severity of asthma atacks in this two weeks
ARS: asthma-related symptoms
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(7.4%) were classified as CS. There was a marked dif-
ference in the distribution of active cigarette smoking
between men and women. In male patients, the mean
duration of asthma and the proportion of atopic
asthma were significantly higher in the CS group
than in the NS group, and the rate of inhaled corti-
costeroid (ICS) and oral sustained-release theophyl-
line (OSRT) use was significantly lower in the CS
group than in the NS group ( Table 3-a ). In female
patients, patient age and rate of oral corticosteroid
use were significantly lower in the CS group than in
the NS group, and the rate of ICS use was signifi-
cantly higher in the CS group than in the NS group
(Table 3-b). There was a significant difference in dis-
ease severity between the CS group and the NS
group in women, but not in men. There was a signifi-
cantly higher prevalence of ambulance use and emer-
gency department visits in the female CS group than
in the female NS group. There was no significant dif-
ference in the Brinkman’s index for men and
women．
ASTHMA CONTROL
The presence of asthma attacks , PEFV , asthma-
related symptoms, cough, sputum and sleep distur-
bance during the two weeks prior to the question-
naire, which reflect relatively short-term asthma con-
trol, are summarized in Table 4. In men, PEFV was
significantly lower, both in the morning and at night,
in the CS group than in the NS group (Table 4-a). In
women, PEFV was significant higher in the CS group
than in the NS group (Table 4-b). In men, there was a
higher incidence of asthma-related symptoms in the
morning and at night, sputum and cough in the morn-
ing, and sleep disturbance, in the CS group than in
the NS group (Table 4-a). Such significant differences
were not found in female patients (Table 4-b).
Asthma attacks during the year prior to the ques-
tionnaire are summarized in Table 5, which indicates
relatively long-term asthma control. There was a sig-
nificant difference in long-term asthma control be-
tween the CS group and the NS group in men, but
not in women (Tables 5-a, b). A significant difference
in satisfaction in daily life was found between the CS
group and the NS group in both men and women (Ta-
bles 6-a, b).
MULTIPLE REGRESSION ANALYSIS AND LO-
GISTIC REGRESSION ANALYSIS (12 DEPEND-
ENT VARIABLES AND 14 EXPLANATORY VARI-
ABLES)
The results shown in Table 4 indicate that the suscep-
tibility of asthma to active smoking may be different
in men and women in our study. However, medica-
tions and background factors , which can influence
control and symptoms of asthma, must be taken into
consideration . Multiple regression analysis with a
stepwise procedure for continuous data, and logistic
regression analysis with a stepwise procedure for
categorical data were performed. Table 7-a shows 14
explanatory variables , and Table 7-b shows 12 de-
pendent variables used in this study.
Tables 8-a, b, c, d and e show the partially analyzed
data. In men, active smoking contributed significantly
to asthma-related symptoms in the morning (Table 8-
a) and at night (Table 8-d), cough and sputum in the
morning (Tables 8-b , c) and sleep disturbance (Ta-
ble 8-e). By contrast, there was no relationship be-
tween smoking and these asthma symptoms in
women.
DISCUSSION
This study analyzed the results of a questionnaire
survey in Niigata Prefecture conducted on 2000. In
this study, the male CS group had a longer duration
of asthma and a higher incidence of atopic asthma,
and the CS group had lower rates of medication with
ICS and OSRT than the NS group (Table 3-a). This
may influence asthma control - less medication in the
male CS group could result in the poor control shown
in Table 4-a. However, regression analysis revealed
that the use of OSRT and ICS did not contribute to
asthma symptoms in men, except that OSRT did con-
tribute to asthma-related symptoms in the morning.
On the other hand, active smoking significantly con-
tributed to asthma symptoms (Table 8), indicating
that the male CS group tended to manifest more
asthma symptoms , including cough , sputum and
sleep disturbance, than the male NS group.
As summarized in Tables 3-b and 4-b, there were
also some differences between the female CS group
and the female NS group. When interpreting these
results, there were several problems. The female CS
group was much younger, had a lower rate of mild
asthma, a lower incidence of oral corticosteroid use,
and a higher incidence of ICS use than the female NS
group. It is well known that PEFV decreases with
age ; the female CS group was significantly younger
than the female NS group, and had a higher PEFV
(Table 3-b). Therefore, Table 4-b may not exclude a
contribution of smoking to asthma symptoms in the
female CS group . However , regression analysis
clearly showed no contribution of smoking to asthma
symptoms in women. This apparently differs from the
situation in men.
The finding of this study that there was a gender
difference in susceptibility of asthma to active smok-
ing was potentially a problem, because previous re-
ports have showed that active smoking induced more
respiratory symptoms, and a greater decrease in lung
function, in women than in men . 16,17 Women with
asthma have been reported to be more affected by
smoking than men.19,20 However, there are possible
explanations for our result. Black male smokers have
been reported to have a more marked decrease in
lung function than black female smokers . 18 This
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Table 8-a Regression analysis of asthma related symptoms in the morning
Exp 
(β)
pS.E.βParametersGender
Exp
 (β)
pS.E.βParametersGender
0.6620.0020.136-0.413PEF1.5790.0110.1790.457use of OSRT
1.4200.0270.1580.351use of OSRT0.001SABA
0.000SABA1.5160.0040.1440.416　on demand
2.0130.000.1460.700　on demand3.0180.0040.3861.105　regular use
2.0760.0560.3830.730　regular use0.046severity (vs. mild)
1.3770.0240.1420.320use of LTRAFemale0.9910.9530.148-0.009　moderateMale
0.6650.0090.156-0.408intercept1.7820.0220.2510.577　severe
0.000smoking (vs. NS)
1.3690.0580.1650.314　ES
2.5800.0000.2050.948　CS
0.3840.0000.212-0.957intercept
CS: curent smoking, ES: ex-smoking, LTRA: leukotriene receptor antagonist, NS: nonsmoking, OSRT: oral sustained-release theophyl-
line, SABA: short-acting beta 2 agonist
Table 8-b Regression analysis of morning sputum
Exp
(β)
pS.E.βParametersGender
Exp
(β)
pS.E.βParametersGender
1.7840.0070.2130.579use of OSRT
Female
0.5690.0040.196-0.564PEF use
Male
0.012SABA0.002severity (vs. mild)
1.5320.0110.1670.427　on demand1.2440.2790.2020.218　moderate
2.1450.0560.4000.763　regular use2.7900.0010.2971.026　severe
0.1380.0000.202-1.982intercept0.007smoking (vs. NS)
0.8480.4710.228-0.165　ES
1.6870.0380.2530.523　CS
0.1860.0000.224-1.681intercept
CS: curent smoking, ES: ex-smoking, NS: nonsmoking, OSRT: oral sustained-release theophyline, SABA: short-acting beta 2 agonist
Table 8-c Regression analysis of morning cough
Exp
(β)
pS.E.βParametersGender
Exp
(β)
pS.E.βParametersGender
1.8660.0030.2080.624use of OCS
Female
0.000severity (vs. mild)
Male
1.1740.0340.0760.161dose of ICS1.0600.7220.1640.059　moderate
1.6090.0040.1660.476use of LTRA2.4940.0000.2430.914　severe
1.1660.0350.0730.154Brinkman’ sindex0.013smoking (vs. NS)
0.1990.0000.108-1.613intercept0.9260.7400.230-0.076　ES
1.6090.0410.2330.476　CS
1.2080.0280.0860.189Brinkman’ sindex
0.2890.0000.205-1.242intercept
CS: curent smoking, ES: ex-smoking, NS: nonsmoking, ICS: inhaled corticosteroid, OCS: oral corticosteroid, LTRA: leukotriene receptor 
antagonist, SABA: short-acting beta 2 agonist
means that the previously reported susceptibility pat-
tern is still controversial. Another is that these stud-
ies were performed outside Japan. Despite the high
prevalence of smoking in Japan, the incidence of lung
cancer has been lower in Japan than in Western coun-
tries (“the Japanese smoking paradox”),24 indicating
that the Japanese may also differ from other races in
their susceptibility of asthma to active smoking. A re-
cent study performed in Japan revealed fewer (but
not significantly fewer) effects of active smoking on
female smokers than male smokers ;9 this result was
similar to our own, except that our study has clearly
demonstrated a significant difference in susceptibility
of asthma symptoms to smoking.
In other advanced countries, the current smoking
rate among asthma patients ranges from 17% to 35%,
with little gender difference.2-9 However, the current
smoking rate among women in this study was lower
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Table 8-d Regression analysis of asthma related symptoms at night
Exp
(β)
pS.E.βParametersGender
Exp
(β)
pS.E.βParametersGender
0.7520.0460.143-0.285PEF
Female
0.003SABA
Male
1.7240.0020.1770.544use of OSRT1.5040.0060.1490.408　on demand
0.000SABA2.3550.0130.3430.857　regular use
2.2070.0000.1490.792　on demand0.005severity (vs. mild)
2.2400.0330.3790.806　regular use1.1080.5050.1530.102　moderate
1.6470.0100.1930.499use of OCS2.1610.0010.2400.771　severe
0.2740.0000.176-1.294intercept0.050Smoking (vs. NS)
1.1100.5540.1760.104　ES
1.6060.0230.2080.474　CS
0.3190.0000.178-1.143intercept
CS: curent smoking, ES: ex-smoking, NS: nonsmoking, OCS: oral corticosteroid, OSRT: oral sustained-release theophyline, SABA: 
short-acting beta 2 agonist
Table 8-e Regression analysis of sleep disturbance
Exp
(β)
pS.E.βParametersGender
Exp
(β)
pS.E.βParametersGender
0.6610.0080.156-0.414PEF
Female
1.1760.0370.0780.162duration of disease
Male
1.5690.0200.1940.451use of OSRT0.000SABA
0.000SABA1.9140.0000.1700.649　on demand
2.2350.0000.1610.804　on demand4.1400.0000.3541.421　regular use
4.0200.0000.3791.391　regular use0.001Smoking (vs. NS)
0.2060.0000.194-1.581intercept2.2650.0000.2240.817　ES
2.1760.0030.2600.777　CS
0.001severity (vs. mild)
1.0070.9700.1790.007　moderate
2.5120.0000.2570.921　severe
0.0940.0000.237-2.361intercept
CS: curent smoking, ES: ex-smoking, NS: nonsmoking, OSRT: oral sustained-release theophyline, SABA: short-acting beta 2 agonist
than this (7.4%), although the Brinkman’s Index was
the same for the male and female CS groups (Ta-
ble 3). Because other lifestyle factors were not exam-
ined in this study , it is uncertain whether active
smoking was independent of other lifestyle factors .
When classification was performed according to
smoking status, unexpected selection related to other
factors in the Japanese female lifestyle may occur. Ta-
ble 3-b showed a significant increase in the rate of ex-
perience of ambulance or ED in female CS group
compared with female NS group, which may be re-
lated with this factor associated with Japanese female
lifestyle. The Japanese lifestyle is now changing to-
ward the Western lifestyle. Therefore further investi-
gation is required．
This gender difference can influence the manage-
ment of asthma. Stopping smoking is one of the most
important steps in the management of asthmatic
smokers, especially in men. It has been reported that
an inhaled beta2 agonist, which can immediately im-
prove asthma symptoms, improved ICS compliance.25
This indicates that relief of asthma symptoms may be
linked to improvement of other important factors in
asthma management . The weaker linkage between
smoking and asthma symptoms in women than in
men could give unexpected results , such as re-
starting smoking. When female asthmatic smokers
quit smoking, it may be important to inform them
that stopping smoking will not always improve
asthma symptoms. Thus, a gender-specific approach
to smoking cessation is needed．
In summary, a questionnaire survey of adult pa-
tients with bronchial asthma, and their attending phy-
sicians in Niigata Prefecture , Japan , was analyzed
with a focus on active smoking and gender differ-
ences . In the male CS group , there were more
asthma-related symptoms, such as morning sputum
and cough, and more severe sleep disturbance than
those in the male NS group. In the female CS group,
however, these symptoms were uncommon. A logis-
tic and multiple regression analysis confirmed these
significant differences between men and women. The
gender differences in susceptibility of asthma to ac-
tive smoking suggest the necessity of gender-specific
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strategies for smoking cessation, although further in-
vestigation is required．
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